middle.news
Cambium Bio Secures $3M Funding Boost to Propel Phase 3 Trials
9:24am on Friday 23rd of January, 2026 AEDT
•
Healthcare
Read Story
Cambium Bio Secures $3M Funding Boost to Propel Phase 3 Trials
9:24am on Friday 23rd of January, 2026 AEDT
Key Points
Received $0.6 million R&D Tax Incentive refund for FY2025
Announced $2.4 million placement from major shareholder ZYBT at 20% premium
Phase 3 trial preparations underway with patient dosing targeted for Q2 2026
Advancing licensing discussions for Elate Ocular in Europe and Middle East
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cambium Bio (ASX:CMB)
OPEN ARTICLE